
Recro Pharma REPH
Annual report 2023
added 03-22-2024
Recro Pharma Book Value 2011-2026 | REPH
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Recro Pharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 58.7 M | 59.9 M | 42.1 M | -14.1 M | -6.71 M | -19.5 M | 28.8 M | 71.6 M | 40.4 M | 18.9 M | 2.34 K | -15.6 M | -13.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 71.6 M | -19.5 M | 19.3 M |
Quarterly Book Value Recro Pharma
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 58.3 M | 54.3 M | 56 M | 59.9 M | 35.2 M | 37.3 M | 39.2 M | 42.1 M | 44.5 M | 26.4 M | -8.72 M | -14.1 M | -14.1 M | -14.1 M | -14.1 M | -6.71 M | -6.71 M | -6.71 M | -6.71 M | -19.5 M | -19.5 M | -19.5 M | -19.5 M | 28.8 M | 28.8 M | 28.8 M | 28.8 M | 71.6 M | 71.6 M | 71.6 M | 71.6 M | 40.4 M | 40.4 M | 40.4 M | 40.4 M | 18.9 M | 18.9 M | 18.9 M | 18.9 M | -12.1 M | -12.1 M | -12.1 M | -12.1 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 71.6 M | -19.5 M | 20.3 M |
Book Value of other stocks in the Drug manufacturers industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | ||
|
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
8 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-651 K | - | 0.86 % | $ 117 M | ||
|
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | ||
|
Canopy Growth Corporation
CGC
|
487 M | $ 1.1 | 2.84 % | $ 118 M | ||
|
Cronos Group
CRON
|
1.71 B | $ 2.64 | 1.35 % | $ 1.38 B | ||
|
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | - | - | $ 2.06 B | ||
|
China Pharma Holdings
CPHI
|
7.75 M | $ 0.59 | 6.08 % | $ 10.3 M | ||
|
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
22.5 M | $ 3.81 | -16.81 % | $ 53.6 M | ||
|
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B | ||
|
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M | ||
|
Evolus
EOLS
|
-23.1 M | $ 5.68 | 37.53 % | $ 366 M | ||
|
HEXO Corp.
HEXO
|
314 M | - | 2.45 % | $ 38.1 M | ||
|
Evoke Pharma
EVOK
|
-2.58 M | - | - | $ 36.6 M | ||
|
Harrow Health
HROW
|
52.1 M | $ 40.02 | 3.65 % | $ 1.47 B | ||
|
Aurora Cannabis
ACB
|
609 M | $ 3.65 | 4.89 % | $ 86.3 M | ||
|
Athenex
ATNX
|
-24.2 M | - | -23.39 % | $ 1.76 M | ||
|
Jupiter Wellness
JUPW
|
-2.17 M | - | - | $ 33.6 M | ||
|
Emergent BioSolutions
EBS
|
649 M | $ 8.95 | 0.39 % | $ 458 M | ||
|
Assertio Holdings
ASRT
|
138 M | $ 12.19 | 2.48 % | $ 866 M | ||
|
Bausch Health Companies
BHC
|
-82 M | $ 5.67 | -0.87 % | $ 2.07 B | ||
|
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | ||
|
Neoleukin Therapeutics
NLTX
|
186 M | - | - | $ 193 M | ||
|
OrganiGram Holdings
OGI
|
306 M | $ 1.4 | 2.19 % | $ 402 M | ||
|
Organogenesis Holdings
ORGO
|
385 M | $ 2.87 | 0.01 % | $ 378 M | ||
|
Sundial Growers
SNDL
|
1.13 B | $ 1.55 | 1.21 % | $ 3.37 M | ||
|
Perrigo Company plc
PRGO
|
2.94 B | $ 11.71 | 2.81 % | $ 1.62 B | ||
|
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | ||
|
Rockwell Medical
RMTI
|
21.3 M | $ 0.91 | 1.03 % | $ 21.2 M | ||
|
Pacira BioSciences
PCRX
|
778 M | $ 22.92 | 3.69 % | $ 1.06 B | ||
|
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | ||
|
OptiNose
OPTN
|
-86.6 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
51.7 M | - | -27.8 % | $ 2.56 M | ||
|
Relmada Therapeutics
RLMD
|
85.4 M | $ 4.79 | 2.57 % | $ 144 M | ||
|
SCYNEXIS
SCYX
|
73 M | $ 0.76 | 1.22 % | $ 36.4 M | ||
|
Solid Biosciences
SLDB
|
137 M | $ 6.14 | 3.02 % | $ 251 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 2.74 | -0.36 % | $ 3.4 M | ||
|
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | ||
|
TherapeuticsMD
TXMD
|
29.3 M | $ 2.25 | 1.35 % | $ 23.5 M | ||
|
Tilray
TLRY
|
3.33 B | $ 7.33 | -0.48 % | $ 4.53 B | ||
|
Veru
VERU
|
32.3 M | $ 2.53 | 0.4 % | $ 341 M | ||
|
Viatris
VTRS
|
21.1 B | $ 14.74 | -1.04 % | $ 17.7 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
46.2 M | - | - | $ 55.5 M | ||
|
cbdMD
YCBD
|
1.96 M | $ 0.75 | -2.76 % | $ 3.23 M |